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ABSTRACT 14 
The class A mec gene complex also carries the psm-mec gene. The psm-mec gene product can be 15 
detected as a peak near 2415 m/z using matrix-assisted laser desorption ionization time-of-flight 16 
mass spectrometry (MALDI-TOF MS). The correlation of a 2415 m/z peak with methicillin 17 
resistance (mecA carriage) in consecutive staphylococcal blood culture isolates was evaluated. A 18 
2415 ± 2.00 m/z peak was observed in 37% (51/137) of methicillin-resistant Staphylococcus 19 
aureus, in none (0/146) of the methicillin-susceptible S. aureus, in 6% (10/180) of methicillin-20 
resistant S. epidermidis, and in 2% (1/63) of methicillin-susceptible S. epidermidis isolates. 21 
Although the sensitivity of the 2415 m/z peak for mecA carriage in S. aureus and S. epidermidis 22 
was low (37% and 6%, respectively), the specificity was high (≥98%). This peak can be 23 
identified during routine MALDI-TOF MS clinical testing, and the analysis adds no reagent cost 24 
and requires minimal time expenditure.  25 
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1. Introduction 29 
Methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus epidermidis 30 
(MRSE) isolates are commonly encountered in clinical microbiology. In addition to causing 31 
increased morbidity and mortality, MRSA has been associated with higher healthcare costs than 32 
its methicillin susceptible counterpart (Tansarli, Karageorgopoulos, Kapaskelis, & Falagas, 33 
2013). Identifying MRSA from clinical samples more quickly and inexpensively would benefit 34 
both the laboratory and healthcare providers. The recent availability of MALDI-TOF MS has 35 
helped laboratories identify organisms more rapidly and at a lower cost (Patel, 2015). MALDI-36 
TOF MS is routinely used only for taxonomic identification of cultured isolates, but the mass 37 
spectra contain rich data that can be used to evaluate more than simply the organism’s species-38 
level identity. For example, MALDI-TOF MS has been used to infer strain lineage, the 39 
production of virulence factors, and the presence of antimicrobial resistance (Josten, et al., 2014; 40 
Josten, et al., 2013; Ostergaard, Hansen, & Moller, 2015; Wolters, et al., 2011; Youn, et al., 41 
2016).  42 
Each mass spectrum is comprised of dozens of mass-charge (m/z) peaks. Some peaks are 43 
more discriminatory than other peaks when attempting to characterize staphylococcal isolates 44 
(Wolters, et al., 2011). Each peak correlates with a biological molecule, and one such molecule is 45 
the phenol soluble modulin, PSM-mec (Chatterjee, et al., 2011). The PSM-mec MALDI-TOF 46 
MS peak first appeared in the peer-reviewed literature in 2002, although it was not recognized as 47 
PSM-mec at the time (Du, Yang, Guo, Song, & Wang, 2002). PSM-mec was later isolated from 48 
methicillin resistant staphylococci, and its doubly-charged (1208 m/z) and triply-charged (806 49 
m/z) ions were identified using high performance liquid chromatography followed by mass 50 
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spectrometry (Kaito, et al., 2011; Queck, et al., 2009).  Recently, PSM-mec identification in S. 51 
aureus using MALDI-TOF MS was thoroughly investigated (Josten, et al., 2014).  52 
The PSM-mec peptide is coded for by the psm-mec gene and is present in the class A mec 53 
gene complex, which is carried by staphylococcal cassette chromosome mec (SCCmec) types II, 54 
III, and VIII (Chatterjee, et al., 2011); which may represent up to half of MRSA infections at 55 
some institutions (David, et al., 2014). PSM-mec does not cause methicillin resistance, and its 56 
biological is still being studied. The peptide is thought to attenuate staphylococcal virulence, and 57 
its expression can vary due to genetic variation of regulatory elements (Kaito, et al., 2013; Otto, 58 
2014a, 2014b). 59 
We evaluated the prevalence, specificity, and possible clinical utility of using the 2415 60 
m/z peak to predict mecA carriage in consecutive clinical isolates S. aureus and S. epidermidis. 61 
Although multiple molecular assays for the rapid detection of mecA are available and often 62 
performed on blood cultures, this testing is not commonly performed for staphylococcal isolates 63 
from other specimen sources, and using MALDI-TOF MS could be a rapid and inexpensive 64 
method of identifying mecA carriage in some staphylococci. Rapid detection of mecA can 65 
decrease the time to appropriate medical management and supports antibiotic stewardship 66 
efforts. This study demonstrates that rapid detection of methicillin resistance is possible in a 67 
subset of clinically isolated staphylococci by simply evaluating data that are already produced 68 
during routine MALDI-TOF MS testing. 69 
 70 
2. Materials and methods 71 
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This study was performed retrospectively using data that had been generated during 72 
routine laboratory testing. The study was performed in accordance with ethical standards 73 
approved by the Cleveland Clinic Institutional Review Board (IRB #15-1641).  No external 74 
funding supported this study.  75 
 76 
2.1 Facility  77 
The Cleveland Clinic microbiology laboratory is accredited by the College of American 78 
Pathologists, and it acts as the clinical microbiology laboratory for the health system’s inpatient 79 
and outpatient services. It also serves as a reference laboratory for outside clients. At the time of 80 
this study, the laboratory was performing blood cultures for as many as seven acute care 81 
hospitals in the Cleveland Clinic system in Northeast Ohio. Over 90,000 blood cultures were 82 
performed in the laboratory in 2015.   83 
 84 
2.2 Routine laboratory methods.  85 
Blood cultures were collected as paired sets of an aerobic and an anaerobic blood culture 86 
bottle with approximately 10 mL of blood in each bottle. These were incubated for up to 5 days 87 
using the BacT/ALERT (bioMerieux; Durham, NC) system. Positive blood cultures containing 88 
Gram positive cocci by direct Gram stain were analyzed using the Verigene Gram-Positive 89 
Blood Culture (Verigene) Test (Nanosphere; Northbrook, IL), a microarray that includes S. 90 
aureus, S. epidermidis, and mecA targets (Wojewoda, et al., 2013); which served as the reference 91 
standard. The Verigene assay was chosen as the reference standard because it is the assay used in 92 
routine testing, produces objective results based on the isolate’s genotype, is an FDA-cleared 93 
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assay, and correlates well with phenotypic susceptibility testing (Wojewoda, et al., 2013).  94 
Positive blood culture broths were also subcultured to agar media, and after overnight incubation 95 
the organism was directly transferred to a target plate and identification was confirmed using a 96 
Vitek MS (bioMerieux; Durham, NC) MALDI-TOF MS system in accordance with the 97 
manufacturer’s in vitro diagnostics (IVD) methodology. Two different Vitek MS instruments are 98 
routinely used in the laboratory. Fine tuning is performed on the Vitek MS instruments every two 99 
weeks to ensure their reliability.  100 
 101 
2.3 Clinical isolates 102 
We sought to obtain at least 200 isolates of each S. aureus and S. epidermidis for 103 
analysis. The study set was comprised of all S. epidermidis blood culture isolates with Verigene 104 
results obtained August through October 2015 and all S. aureus blood culture isolates with 105 
Verigene results from March through November 2015. Cultures of S. aureus or S. epidermidis in 106 
which mecA was detected by Verigene were considered MRSA or MRSE, respectively. 107 
Demographics, clinical characteristics, severity of disease, and diagnosis were not considered or 108 
analyzed. Polymicrobial blood cultures were excluded from this study. Only a single isolate from 109 
each subject was included in the study.  110 
 111 
2.4 2415 m/z MALDI-TOF MS peak analysis using Vitek MS.  112 
Mass spectra collected during routine clinical identification testing (described above) 113 
were manually examined retrospectively for a 2415 m/z peak by using the Vitek MS Acquisition 114 
Station software version 1.4.2b (bioMerieux; Durham, NC). The interpreters of the mass spectra 115 
7 
© 2016. This manuscript version is made available under the CC-BY-NC-ND 4.0 license 
http://creativecommons.org/licenses/by-nc-nd/4.0/   
DOI: http://dx.doi.org/10.1016/j.diagmicrobio.2016.08.001 
 
 
 
were not blinded to the Verigene results, but the spectra were interpreted objectively in the 116 
manner described hereafter. The mass spectra were viewed by zooming into a window spanning 117 
500 m/z (approximately 2200-2700 m/z). Prominent peaks in this window are automatically 118 
labeled by the software without user intervention. The criteria used to identify prominent peaks 119 
are incorporated into the Acquisition Station software, and these peaks are automatically labeled 120 
by the software. Only these labeled peaks were considered in the analyses. In the initial analyses, 121 
spectra containing a peak labeled as 2415 ± 4.00 m/z were considered positive for a 2415 m/z 122 
peak, which is the effective detection window described by Josten et al (Josten, et al., 2014). All 123 
other spectra were considered negative for the 2415 m/z peak. In post hoc analysis, spectra 124 
containing a peak labeled as 2415 ± 2.00 m/z were considered positive for a 2415 m/z peak, and 125 
all other spectra were considered negative.  126 
 127 
2.5 USA strain characterization 128 
A set of 12 well characterized S. aureus strains (USA100-USA1200 strains) were tested 129 
for the presence of the 2415 m/z peak using both the Vitek MS (methods described above) and 130 
the Bruker MicroFlex (Bruker Daltonics, Billerica, MA). Colony growth from agar medium was 131 
directly transferred to a target plate. Mass spectra were generated using the Bruker Biotyper 132 
system after calibration with Bacterial Test Standard (BTS) (Bruker Daltonics, Billerica, MA).  133 
After generating the mass spectra, flexAnalysis software version 3.4 (Bruker Daltonics, Billerica, 134 
MA) was used to perform smoothing and baseline subtraction on the spectra, and flexAnalysis 135 
was used to subjectively evaluate the spectra for the presence or absence of the 2415 m/z peak. 136 
Clinical isolates were not tested using the Bruker system. 137 
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 138 
2.6 Statistical analysis 139 
The MedCalc online statistical software (Version 16.2.1) “diagnostic test evaluation 140 
calculator” was used to calculate sensitivity, specificity, positive and negative predictive values, 141 
and exact Clopper-Pearson confidence intervals ("Diagnostic test evaluation calculator," 2016).  142 
 143 
3. Results 144 
This study examined 283 consecutive S. aureus and 243 consecutive S. epidermidis blood 145 
culture isolates from unique subjects. Verigene identified 56% (137/283) of the S. aureus isolates 146 
as MRSA and 74% (180/243) of the S. epidermidis isolates as MRSE. The 2415 ± 4.00 m/z peak 147 
(Figure 1) was identified in 39% of the MRSA isolates (Table 1) and 6% of the MRSE isolates 148 
(Table 2). In both S. aureus and S. epidermidis, the specificity of the presence of a 2415 ± 4.00 149 
m/z peak for the detection of the mecA gene was 97%. 150 
  151 
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 152 
Figure 1  153 
The Vitek MS Acquisition Station software depicts MALDI-TOF mass spectral peaks from two 154 
methicillin resistant Staphylococcus aureus strains. The software automatically labels prominent 155 
peaks, and these were the peaks considered in the analyses. One strain is an USA100 strain (top), 156 
and the other strain is an USA300 strain (bottom). The USA100 strain has the class A mec gene 157 
complex with the PSM-mec peak near 2415 m/z (arrow), and the USA300 strain lacks the class 158 
A mec gene complex and the PSM-mec peak. The x-axis depicts mass-charge, and the y-axis 159 
represents percent intensity. The widths of the bars and the size of the x-axis labels were 160 
modified after screen capture to improve figure clarity, but the original screen captures are 161 
available (S2 Figure & S3 Figure). 162 
 163 
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Table 1  165 
Results of using the 2415 m/z peak to predict mecA carriage in 283 consecutive S. aureus blood 166 
culture isolates from unique patientsa  167 
When compared to mecA 
carriage determined by Verigene 
Peak identified in S. aureus  
by Vitek MS  
2415 2415 
± 2.00 m/z ± 4.00 m/z 
Sensitivity  
0.37 (51/137) 0.39 (53/137) 
CI 0.29-0.46 CI 0.30-0.47 
Specificity 
1.00 (146/146) 0.97 (142/146) 
CI 0.98-1.00 CI 0.93-0.99 
Positive predictive value 
1.00 (51/51) 0.93 (53/57) 
CI 0.93-1.00 CI (0.83-0.98) 
Negative predictive value 
0.63 (146/232) 0.63 (142/226) 
CI 0.56-0.69 CI 0.56-0.69 
a CI, 95% confidence interval. 168 
Table 2  169 
Results of using the 2415 m/z peak to predict mecA carriage in 243 consecutive S. epidermidis 170 
blood culture isolates from unique patientsa 171 
When compared to mecA 
carriage determined by Verigene 
Peak identified in S. epidermidis  
by Vitek MS 
2415 2415 
± 2.00 m/z ± 4.00 m/z 
Sensitivity  
0.06 (10/180) 0.06 (10/180) 
CI 0.03-0.10 CI 0.03-0.10 
Specificity 
0.98 (62/63) 0.97 (61/63) 
CI 0.91-1.00 CI 0.89-1.00 
Positive predictive value 
0.91 (10/11) 0.83 (10/12) 
CI (0.59-1.00) CI (0.52-0.98) 
Negative predictive value 
0.27 (62/232) 0.26 (61/231) 
CI 0.21-0.33 CI 0.21-0.33 
a CI, 95% confidence interval. 172 
 173 
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Analysis of the actual mass-charge ratios of isolates with a peak in the range of 2411-175 
2419 m/z showed a roughly normal distribution of the mass-charge ratios (Figure 2 & S1 176 
Dataset). In S. aureus, narrowing the PSM-mec peak range from 2415 ± 4.00 to 2415 ± 2.00 m/z 177 
eliminated the 4 “false positive” methicillin-susceptible S. aureus (MSSA) isolates, along with 2 178 
MRSA isolates that were outliers (Figure 2). By narrowing the mass-charge ratio to 2415 ± 2.00 179 
m/z, the specificity of predicting mecA carriage in S. aureus reached 100% (Table 1). Similarly, 180 
the specificity of this prediction for MRSE increased to 98% (Table 2).  181 
When considering only MRSA isolates with a 2415 ± 2.00 m/z peak, the mean mass-182 
charge ratio was 2414.55 (standard error of the mean of 0.091) with a standard deviation of 0.65. 183 
The peak in MRSE isolates had a mean mass-charge ratio of 2414.98 (standard error of the mean 184 
of 0.29) and a standard deviation of 0.90. 185 
The set of twelve USA S. aureus strains contained three isolates with a detectable 2415 186 
m/z peak using both Vitek MS (Figure 1) and Bruker Biotyper (Figure 3): USA100, USA200, 187 
and USA600. These strains carry SCCmec type II, which contains the class A mec gene complex 188 
that includes psm-mec. The nine other strains did not have the class A mec gene complex and did 189 
not have a 2415 m/z peak. When the twelve strains were analyzed using the Bruker MicroFlex, 190 
high intensity peaks were exclusively observed in USA100, USA200, and USA600. However, 191 
these peaks had a slightly lower mass-charge (2412 - 2414 m/z range) than the peaks detected 192 
using Vitek MS.  193 
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 195 
Figure 2 The distribution of the 2415 ± 4.00 m/z peaks identified in 57 blood culture isolates of 196 
S. aureus is depicted by a box-and-whisker plot (top) and a histogram (bottom). The box-and-197 
whisker plot depicts the quartiles of peak distribution. Within the histogram, the four isolates 198 
lacking mecA are represented by hatched bars, and the 53 isolates of MRSA are represented by 199 
open bars. The vertical dotted lines represent a cut-off of 2415 ± 2.00 m/z, which improves the 200 
specificity of using the 2415 m/z peak to predict mecA carriage in S. aureus. 201 
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 203 
Figure 3  204 
MALDI-TOF mass spectra from two methicillin resistant Staphylococcus aureus strains obtained 205 
using Bruker Biotyper are depicted. One strain is an USA100 strain (top), and the other strain is 206 
an USA300 strain (bottom). The USA100 strain has the class A mec gene complex with the 207 
PSM-mec peak near 2415 m/z (arrow), and the USA300 strain lacks the class A mec gene 208 
complex and PSM-mec. The x-axis depicts mass-charge, and the y-axis is arbitrary units x 104. 209 
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This figure was modified from flexAnalysis screen captures. The original screen captures (S4 & 210 
S5 Figures) and additional screen captures (Figures S6 & S7) are available.   211 
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4. Discussion 212 
Our findings demonstrate that the 2415 m/z peak predicts methicillin resistance with high 213 
specificity in S. aureus and S. epidermidis. This peak corresponds to the mass-charge ratio of the 214 
PSM-mec protein found in isolates with a class A mec gene complex, which has been previously 215 
described (Josten, et al., 2014). This is the first report of an attempt to demonstrate the feasibility 216 
of this method in a clinical laboratory setting. 217 
 In this study of consecutive blood isolates of S. aureus, 56% carried mecA. This carriage 218 
frequency is similar to the 57.1% average reported at five other medical centers across the United 219 
States (David, et al., 2014). Also, our finding that 37% of the MRSA isolates studied were 220 
positive for the 2415 ± 2.00 m/z peak is similar to the prevalence of the class A mec gene 221 
complex found in MRSA isolates at other centers (David, et al., 2014), although the mec class of 222 
these MRSA isolates was not evaluated in our study.  223 
Our post hoc analysis demonstrated that narrowing the detection range from 2415 ± 4.00 224 
to 2415 ± 2.00 m/z increased the specificity of this peak for predicting mecA carriage from 97% 225 
to 100% in S. aureus. This was a post hoc analysis, and the finding should be confirmed by 226 
studies in other laboratories using their own endemic strains and MALDI-TOF MS 227 
instrumentation.  228 
Notably, the current study was performed using two Vitek MS systems with the IVD 229 
software package that has been cleared by the U.S. Food and Drug Administration, whereas a 230 
previous study was performed primarily using the Biflex II system (Bruker Daltonic, Bremen, 231 
Germany) (Josten, et al., 2014). Because the analysis can be performed using standard clinical 232 
software, it may facilitate the application of the analysis to routine clinical microbiology 233 
16 
© 2016. This manuscript version is made available under the CC-BY-NC-ND 4.0 license 
http://creativecommons.org/licenses/by-nc-nd/4.0/   
DOI: http://dx.doi.org/10.1016/j.diagmicrobio.2016.08.001 
 
 
 
practice. Bruker has recently released software that would automate this analysis; the MBT 234 
subtyping module is an RUO software solution designed specifically to detect the PSM-mec 235 
peptide in S. aureus ("Bruker Introduces Important MALDI Biotyper Enhancements at ECCMID 236 
2016: New Disposable MBT Biotargets 96, MBT Subtyping and Carbapenem Resistance Tests," 237 
2016). Using this software, if an isolate is identified as S. aureus, the software automatically 238 
interrogates the mass spectrum for the PSM-mec peak and infers presumptive identification as 239 
MRSA if the peak is present. Software solutions like this will foster routine clinical testing and 240 
reporting of the PSM-mec peak. 241 
Of the twelve well characterized USA S. aureus strains analyzed in our study, only those 242 
with the class A mec gene complex yielded the 2415 m/z peak. This was true using both the 243 
Vitek MS (Figure 1) and the Bruker Biotyper platform (Figure 3). However, PSM-mec’s mass-244 
charge appeared slightly lower using the Bruker platform (~2413 m/z) than using the Vitek MS 245 
systems, which was corroborated by another recent study (Budvytiene, Moon, Shi, & Banaei). 246 
Until clinical microbiology has more experience with PSM-mec detection, each laboratory 247 
should verify the mass-charge range which is most appropriate to use in each laboratory.  248 
Data from this study are limited in that only blood isolates from our institution were 249 
examined using our clinical instrumentation. The broader application of this study to other 250 
specimen sources, other geographic regions, and other laboratory instrumentation has not been 251 
evaluated. Verigene detection of mecA was used as the gold standard for determining methicillin 252 
resistance in this study, and its concordance with other methods for detecting mecA has been 253 
reported to be about 98% (Buchan, et al., 2013; Dodemont, De Mendonca, Nonhoff, Roisin, & 254 
Denis, 2015; Mestas, Polanco, Felsenstein, & Dien Bard, 2014). It should be noted that the PSM-255 
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mec peptide is only detectable when cells are deposited directly on the target (Josten, et al., 256 
2014). It is thought that ethanol extraction preparation washes away the PSM-mec peptide 257 
(Josten, et al., 2014; Szabados, Kaase, Anders, & Gatermann, 2012). It is not clear if PSM-mec 258 
detection is possible when using bacterial cells obtained directly from broth cultures (e.g. 259 
positive blood cultures). Because many MRSA and MRSE isolates carry a mec class other than 260 
class A, the absence of the 2415 m/z peak is not diagnostically informative and could be viewed 261 
as a limitation. The strength of analyzing spectra for the presence of the 2415 m/z peak is not in 262 
its sensitivity of detecting MRSA but in the specificity afforded when the peak is identified. 263 
One isolate of S. epidermidis yielded a peak at 2415 ± 2.00 m/z even though no mecA 264 
gene was detected, and it tested susceptible to oxacillin using routine phenotypic methods. This 265 
isolate’s original spectrum was reexamined, and the 2415 m/z peak that was identified and 266 
labeled by the Vitek MS Acquisition Station software had such low intensity that it was not 267 
detectable using subjective gestalt (Figures S8 & S9), which is in contrast to most other isolates’ 268 
2415 m/z peaks. This false positive result suggests that the specificity of the assay could be 269 
improved if the relative intensity of the 2415 m/z peak was required to reach a minimum 270 
threshold before being identified as positive. Alternately, a minimally acceptable ratio of 2415 271 
m/z with a second peak that is consistently encountered in the taxon’s mass spectrum could be 272 
used for objective evaluation of 2415 m/z peak intensity. Vitek MS Acquisition Station software 273 
is not designed for this type of analysis, so subjective interpretation or additional software 274 
features would be required to add an intensity criterion to the methodology used in this study.  275 
One study examined the use of the 2415 m/z peak to identify MRSA with the class A mec 276 
gene complex, and they found that the sensitivity of the assay was significantly improved by 277 
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excluding isolates with agr dysfunction (where agr dysfunction is identified by the absence of a 278 
delta-toxin peak at 3007 m/z) (Josten, et al., 2014). Although this approach is appropriate when 279 
attempting to use MALDI-TOF MS for strain typing, this approach is not necessary when only 280 
using the 2415 m/z peak as a marker of methicillin resistance. We previously examined this 281 
approach and concluded that when using the 2415 m/z peak as an early laboratory marker of 282 
methicillin resistance, assessing agr function increased the complexity of the analysis without 283 
improving the positive predictive value (Rhoads, Wang, Harrington, Procop, & Richter).   284 
Although the 2415 m/z peak has been previously reported in coagulase negative 285 
staphylococci (Josten, et al., 2014), this is the first study to describe the prevalence of the 2415 286 
m/z peak in S. epidermidis clinical isolates. It is known that MRSE genetic resistance types are 287 
diverse and varied (Cherifi, et al., 2013; Garza-Gonzalez, Morfin-Otero, Llaca-Diaz, & 288 
Rodriguez-Noriega, 2010), and our finding that only 6% of MRSE isolates were positive for the 289 
2415 m/z peak is not surprising. In spite of the low prevalence of the 2415 m/z peak in MRSE, 290 
identifying the peak in an isolate of S. epidermidis still had a high positive predictive value for 291 
identifying mecA carriage (Table 2). 292 
Strengths of MALDI-TOF MS peak identification are simplicity and speed. An informal 293 
time study determined that it took less than 30 seconds to use the Vitek MS Acquisition Station 294 
software to retrieve a saved spectrum, identify the presence or absence of the 2415 m/z peak, and 295 
record the results. Although manual analysis is rapid, easy, and inexpensive, ideally this analysis 296 
would be performed by software in the future, which is similar to other MALDI-TOF MS 297 
resistance marker analysis (Youn, et al., 2016). 298 
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In the future, MALDI-TOF MS data will likely be used in the clinical laboratory for more 299 
than taxonomic identification of microorganisms. The finding of the 2415 m/z peak could be 300 
combined with more sophisticated MALDI-TOF MS software analyses to provide computer-301 
interpreted staphylococcal strain lineage information (Camoez, et al., 2016; Josten, et al., 2014; 302 
Josten, et al., 2013; Wolters, et al., 2011), or the 2415 m/z characterization could be combined 303 
with other strain classification criteria to infer a strain type ("Use of an Inferred PFGE 304 
Algorithm, Emerging Infections Program / Active Bacterial Core (ABCs) Surveillance Invasive 305 
MRSA Project," 2009). For example, most MRSA strains with SCCmec Type II are classified as 306 
USA100 by inferred pulse field gel electrophoresis (PFGE) typing ("Active Bacterial Core 307 
Surveillance (ABC) Report Emerging Infections Program Network Methicillin-Resistant 308 
Staphylococcus aureus, 2013," 2015), and the PSM-mec peak in an isolate’s mass spectrum 309 
could be used as a surrogate of SCCmec Type II detection.. Discriminating MALDI-TOF MS 310 
peak patterns could be used routinely by the clinical laboratory in partnership with infection 311 
prevention practitioners to monitor circulating bacteria strains (Spinali, et al., 2015; Youn, et al., 312 
2016). Ideally, this surveillance would occur passively by continuous computerized interrogation 313 
of the mass spectra collected within the microbiology laboratory (Rhoads, Sintchenko, Rauch, & 314 
Pantanowitz, 2014; Youn, et al., 2016).  315 
In summary, the absence of the 2415 m/z peak is not diagnostically informative, but its 316 
presence in an S. aureus or S. epidermidis clinical isolate is highly specific for predicting mecA 317 
carriage. Recognizing the presence of this 2415 m/z peak could expedite the identification of a 318 
subset of methicillin-resistant staphylococci (e.g. USA100 strains) without adding any reagent 319 
cost and only minimal labor.  320 
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Supplementary material descriptions 330 
S1 Dataset. Exact values of peaks in clinical isolates. Two sheets in an Excel (Microsoft, 331 
Redmond, CA) document contain results for S. aureus and S. epidermidis clinical isolates for 332 
peaks in the range of 2415 ± 4.00 m/z. The values were determined by Vitek MS Acquisition 333 
software as described in the methods section. 334 
 335 
S2 Figure. Screen capture of the Vitek MS Acquisition software displaying results of 336 
USA100. 337 
 338 
S3 Figure. Screen capture of the Vitek MS Acquisition software displaying results of 339 
USA300. 340 
 341 
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S4 Figure. Screen capture of the Bruker flexAnalysis software displaying results of 342 
USA100. 343 
 344 
S5 Figure. Screen capture of the Bruker flexAnalysis software displaying results of 345 
USA300. 346 
 347 
S6 Figure. Screen capture of the Bruker flexAnalysis software displaying results of all 12 348 
USA strains. USA100, USA200, and USA600 strains are depicted in red. Other strains are 349 
depicted in blue. 350 
 351 
S7 Figure. Screen capture of the Bruker flexAnalysis software displaying zoomed in results 352 
of all 12 USA strains. USA100, USA200, and USA600 strains are depicted in red. Other strains 353 
are depicted in blue. 354 
 355 
S8 Figure. Screen capture of the Vitek MS Acquisition software displaying results of the 356 
false positive S. epidermidis isolate. The 500 m/z window used in the study is depicted. The 357 
software automatically identified and labeled a peak at 2416.8 m/z, but this peak was not 358 
subjectively evident. 359 
 360 
S9 Figure. Screen capture of the Vitek MS Acquisition software displaying results of the 361 
false positive S. epidermidis isolate. A zoomed in window of approximately 50 m/z is depicted. 362 
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The software automatically identified and labeled a peak at 2416.8 m/z, but this peak was not 363 
subjectively evident. 364 
 365 
  366 
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